feb0305

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, B0IIIAuBo/Iru3GStHcShe1jkgFlOOA8yYSw+95Owbxg+WCkqOcGcIIyuns1fEGz /mPQqO848Ip+rc1doT43CQ== 0000950103-05-001425.txt : 20050516 0000950103-05-001425.hdr.sgml : 20050516 20050516103559 ACCESSION NUMBER: 0000950103-05-001425 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20050512 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20050516 DATE AS OF CHANGE: 20050516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29630 FILM NUMBER: 05831890 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 BUSINESS PHONE: 1264333455 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 8-K 1 may1205_8k.htm feb0305_8-K




UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 12, 2005

Shire Pharmaceuticals Group plc

(Exact name of registrant as specified in its charter)

England and Wales

(State or other jurisdiction of incorporation)

0-29630		98-0359573
(Commission File Number)		(IRS Employer Identification No.)

Hampshire International Business Park, Chineham, Basingstoke,
Hampshire RG24 8EP England

(Address of principal executive offices) (Zip code)

Registrant’s telephone number, including area code 44 1256 894 000

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events

Shire Pharmaceuticals Group plc has issued the press releases attached as Exhibits 99.01 and 99.02 which are incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

	(c)	Exhibits. The following exhibit is filed herewith:

99.01		Press Release dated May 12, 2005
99.02		Press Release dated May 12, 2005

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE PHARMACEUTICALS GROUP PLC

By:	/s/ A C Russell

	Name:	Angus Russell
	Title:	Chief Financial Officer

Dated: May 16, 2005

EXHIBIT INDEX


Number	Description

99.01	Press Release dated May 12, 2005
99.02	Press Release dated May 12, 2005

EX-99.1 2 may1205_8k-ex9901.htm

EXHIBIT 99.01

Hampshire International Business Park
Chineham Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com

Press Release

12 May 2005

Shire Pharmaceuticals Group plc (the "Company")

The Company announces that on 11 May 2005 the following Directors were granted options over ordinary shares of £0.05p each in the Company pursuant to the rules of the Shire Pharmaceuticals Group plc 2000 Executive Share Option Scheme (the "Scheme") at a price of £5.585p per share, as follows:

Director	Number of Shares over which Options granted

M Emmens	295,000

A C Russell	195,000

These options are subject to performance criteria and are exercisable at any time between 3 and 10 years from the date of grant.

As a result of this grant, Messrs Emmens and Russell have options over 1,557,885 and 916,300 ordinary shares of £0.05p, respectively, pursuant to the rules of the Scheme.

In addition, on 11 May 2005, rights to acquire ordinary shares of £0.05p each in the Company at a price of £5.66p were awarded to the following Directors pursuant to the rules of the Shire Pharmaceuticals Group plc Long Term Incentive Plan (“LTIP”):

Director	Rights to acquire

M Emmens	97,468 ordinary shares

A C Russell	63,217 ordinary shares

The LTIP awards are subject to performance criteria and will become transferable to the Directors in 2009. At the discretion of the Remuneration Committee, the awards may be satisfied with ordinary shares or cash.

As a result of this award Messrs Emmens and Russell have the right to acquire 283,687 and 203,592 ordinary shares of £0.05p, respectively, pursuant to the rules of the LTIP.

As the Company has been in possession of unpublished, price-sensitive information since the publication of its 2004 results, these annual awards and grants have been made at the earliest opportunity following the publication of all such information.

T May
Company Secretary

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160

	Brian Piper (North America)	+1 484 595 8252

Notes to editors

Shire Pharmaceuticals Group plc

Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.

For further information on Shire, please visit the Company’s website: www.shire.com.

GRAPHIC 3 ex9901x1x1.jpg GRAPHIC begin 644 ex9901x1x1.jpg M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_ MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"``[`*(#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BBBB@`H MHKYD_:^_:R^$G[%/P)\7?'WXS:LVG>%O#206=A86JB75O$_B;4R\.@^%]$MB M0UQJ6KW:^6N`4M;9+F^GQ;VLK#?"X7$8W$T,'A*-3$8K$U:=##T*47.K6K59 M*%.G"*U'M0U..#3_#OP@LY[GQ4;>Y8VUG_PD/C6Z1WLK:7* MRWDEQ+9Z5!.&87"1**_/GQM^UK^VI\/[B^?Q!^U]\5;OQU9ZG/IFH:;H'C75 M=5M-*EL;B<71U#Q##)_8[WEMJ:2VTME9"<"6.21+F:`QD_MF`\"<^Q%*'U[. M,JR_&32E]12K8RK2C)VBZTZ*C3A=W5X.I"Z:4Y,^;K<482'O4FR2=KMVL?ZF%_J6G:5;M=ZI?V6FVJ??N;^Z@L[=."?FFN)(X MUX!/+#@$U#I>MZ-K<4D^BZOIFKP1.(Y9M+O[74(HY",A))+269$,/B%^T!X=MW1=9\%^*?B=XQT.PUN!0B`3WN@7 MUM/#)'&K;#'&%=FQ)\I-?UV?LT_"+]F[XS_LX?#_`/;M_P"";?C_`.*?P5^, M'P]\;?#6P\=_!T^/_$?BSPOJ7BBY\6^%;#Q1\'_'?A?4[J[MYK/Q3IVO266E M>)((U6:PO[._,T4$=V(>'B+PD?#-#"5,?G=62QE6.&AC:.5<^58?&59ZBHT4I4DYNC.K:M.C%7G4A'V?LY. M+T]FJG,UJVNG]35%?YRGQZ_X+A?\%*_!OQS^-'A#P_\`M`3V6@>%?BS\1O#F MAV7_``CFD2?8]'T3QCK.F:9:^8T>YQ;V5K!"';YFV;CR37]P_P#P33^+GCWX M\_L'_LP?&#XH:R?$/Q`\?_#*PUWQ5K9MXK4ZEJDFH:C;R71MX0(HF>*WB#*@ M"Y!..:^;XL\.(E5A.IAYXE.?M\*Z(N@Z7 M'[*0V\`$49BTO2;&W(0`,8=Y^9C7 MWW$?A[FW#.097Q#C,7@*^$S6IA*=&EAI8AXBG+&X*KCJ7M8U:%.FE&E1G&?+ M4DU.R2<7S+R\'FV%QV)KX6BJBJX?G]ISQ2C[E14Y MEQI7P?\`@AX65]4UB\U:=5M['6O%,%@)[G2?#\-[<6^%DB%[JN)(M/AE*2,O MH97E6/SK'4,NRW#SQ.+KMJ$(V48PBG*I6JU)-0HT*4$YUJU24:=.$7*'U*:W@OQY;_P`%_P#_`()F^,?VW_@OX.^,'P4TZYUW MXY_L]V_B1K/PA#/&C>.OAQKD,&I^)=%TN%P/M/BO3-1T73=2\.VB,'U%)=6T MR!)+V]LT;]1X.Q/"G#_$V5X"&8^UQ56=?#9CQ6HP6$R^K5H5*4,/D4<1&5.% M.K5:PU?.\91F_8U9SP^'P])NL_%Q\,;BL'7J^R3A&,9T#_&'_`((Y>+_@I^V[^W`_PM\2>!_!/P/_`&>OA/\`"K7_ M`!5\*OV?_"]RNF+\3_$]AK_A_P`.6%W\4/%#O!KWQ%UV'0-;OO$&JZ5)>IIE MSJMJD\&FO96&_BIHFE M6UM9+!\2O#$.K:I+9VL:0Q1?VSI]SIDXE$*!#XZCF'#F;TZ.'I8:G2AEN(Q6*HJ%2+E.>(I8J#K>WK8F/VY?V7/VK?B5X M8^,GP*^*'PZ^!OQ.^$.I7FLW?BW0Y;+PZGQ&\%^(_#=UX)O5:21XXM5;2=2\ M6643H@DF22,,W^BPE/1OV:O^#J/P7JLT>D_M5_`75/"&YHD7Q?\`"O4&\3:9 M$AD83W.I:'J,=CJZ[(@KI!I4-\[N609X)_J2^!'Q_P#A#^TO\-]!^+'P3\<: M)X\\$^(;.VNK34]'NXYI+.6XMX[AM-U>S#?:=*U:T$HBO=-O8X;FVF5XY$!4 MU\5Q3Q)Q[D7"*N':-;"U\)_9T<]K5JN+=:4)*KAJKQ-&K4P\L7AU"DX. MK*-6#X-;^$%I!X=T&WB?5?%7B.:UU/6I;E=$\/V9:_O8X$4^=.$6!&(3S"_R MU_`I^U%_R(.3Y'FO#N2U>),U>4Y+EV)P^+Q56G%RQ.)E+` MU:%'!X5*G5?M:LJCFW&C5FJ=.?+#>._#=M> M_P!F:Q#`&M-;\-ZMY$5U_97B+1;C;>Z3?FWFBF6&X3;)&^8WEWZ:5?VUW,IN(1:W0AGGMTD/\`@WP_:6\0_`G_`(*._"GP M,NNWUIX`_:'CUSX4>,="6=SIFHZO>Z#J>K>`=1>S9Q;C5+'QAI>E6%M?;?M$ M>GZMJ=I&6%ULK\XS?PPX-S7A#&<2<%8['5I83"XG%TO;5I5J6)C@82J8O#5: M-6A1KT,3[.G/DUBE4<+TW3FI+WL/GN98?,J>!S6C3@JLH03A'E<'5:5.HI*4 MHSIW=IOHKNZ<6G_3S^TS^WC_`,$2OAO\?/BKX%_:`\"^%M0^-'ACQ9>:9\1[ MV\^#-WKUU=>)8HH'NIIM82%DU&1HWA!N58A@`.U?6MW_`,%,O^"?/[,O[)WP M`^-UAJ]UX$_9P^,.H>*=!^#=MX:\!ZE%"USH6KZ_)XA@'AVT03:3%_:UAK-P MS2J%N)I&E&3."?X-/^"PG_*3G]M/_LMFN_\`I%IM?>G[=G_*!W_@D1Z_\+&^ M.W_J3_$W_P"M79B/#/)J^`X$5;,\_K4\^QF!HXNA7S*%2A1A5X2DHHYUB/:YPXT,)"6"IUITY0HN,ZCAB84U[62FG) M..LKEK']C'[(W_!5']C?]M_QOXH^'O[/_CO6M>\2>#?!EUX_P#$$6N> M%]2\-V5EX8LM7TC0[F^-_J6RW8Q7^N:>K1;@PB>28D)$QKY._:%_X.#O^">? MP$\::KX!@\8^)?BIX@T*]NM.UF?X<:%-J_AZROK*Z>SO+-/$3%=.N[FUN(9X MYH[=W56BP'8.A/\`G]?!#]H+XL?!#2_C!X;^$NIW>BZE\??ARGP;\2ZCI'VM M?$1\)ZCXO\,>*-0TKP_/92)4R2,@5UJ\9X2\"K&E&6*J5:ZH0G4C&I+EA2H4HNG!*=6J^>,5%/B+-,90A#!82-;%)3GB M)0I3E3IQY[4XPBYN\G'WI.4K:I15[V_OI^#_`.T=\,_C%^SOX`_:>TS5E\,_ M"WX@^`-)^)&GZKXOE@T,Z7XR6_@EUEKN2.&REB@8"9))!A_D7&/"MM:^-FU75;6=!J_ASPQJ]]=^'-/T>2,V?]I:5>ZAZ=H^A1ZMXL\96VE MW)LKOQ$8M0N+*ST[P[)?17=CI]P99+J^DM)KF*$VC0RR>30\,.$,DRS$<1\9 M9OB:&5XG%3>4X;!U'S2P5>=2>7>TJ0H5L1BL5B,*HUY4J-.FJ4%*523:G[/J MJYYC\3BOJ.58>$ZU*/[^K65HJ44E4:BW%0C";Y;R;_\` M!.#X@ZM;:-XA\5>.?AA/=2*B:AXS$WT>@6X.XM)?:U9^;;6<487+22*1R`` M37[G>$_%WA?QWXT.^M]2TO4K&ZB6:"YM;NV> M2*1'C=20&#H24D575E'^?A_P5;_X(0>,?V!_APOQ_P#A1X\OOC!\%-/U'2=' M\;'4M'72_%W@2XUB8V=AK>I6MG-=6-UX7NM3DL]*_M"&X\^TU"^M4O((HIX9 M']G_`.#(H+GX+?&F]UR7X>-K=U(9O!7Q8728;K3 M-)T>ZGD,=MHGC:VT>?21I"[(CXHGTJ6S03ZA=B7AS[PUX9S+AC$<5<`9CBL; M0P4*U7%X/$S=1RI8:FJN*A34Z%#$T,5AZ3]LZ%:-1UJ;7LVN:GSZ83.L=1Q\ M,NS>A3I5*SBJ5:E=1;E[L'O.,XU)IQYHN/)+W91T=O[RJ***_!CZH_.?_@IW M_P`%!?`?_!.[]FS6OBEKQBU;XB^*?[1$?!?P2#NG\4>/9=+N;FTGO%4A[?P MUX>58]4\27YPL5JL-C!YFHZEI]O/^='_``1F_P""?OCJ75]0_P""GG[:=V_C M;]K+]HFR3Q;X+AUBVE@G^&?@OQ-ID<,-U<:5<0QPZ9XGUW1/L=K86-L"GA;P MF+72HY!>WFH16GXS?\%"?BC+^W%_P7W^#O[.7C;4KF_^"?PE_:%^#WP.L/!^ MI3-%HTEM%K/A76/BUMM-PB-_XTULZCH$E[_Q\7FFV&A6P8+;1*/[QE545415 M1$4*B*`JJJC"JJ@`*J@`````#`&*_5L[H5.".$;\9Y>LTSO') MEE%3V88FM4UH9;65#"TG> MSQ"B_:XF::5Y)/DH](QO)>\TQU?.'C']L#]ECX>^)M7\&>.?V@OA)X3\6:!< M1VNM^'-?\<:%IFL:51W%M*]KGW4GP\_:=\/^&_%NDZREO+]@M/&WA/PWI/@CQ? MX9ENO+$)U%(?#ND^*!%OWM9>(X@H;[/*P\/P^X6R_C#/*F38_,JN6N6!K8G" M3HTZ=2>(Q%"I0YL.HU)15_JTZ]?2[Y:$NESIS?'U,MPOUJG0^L)5(0G'F<5" M,E+WW)1E9*2C';>2/Z__`(O_`+%G_!-G_@IEI]UXYUSPI\,OB[J&E7TVA7?Q M1^&&N6EKXBM-32UM[M]/U3Q%X9F\O4KV"TO;.XCBUZ'49;>":`Q!(7"M^+'Q M]_X-5_AMK>J:AJ_[.'[16N^"K.<3/9>#_B7H2>([.VE8DQ(WBO17M;\VZ?*A M'_"//(!EMS'Y3^4'_!!__@JOX+_8$\?>._A-\=YM3M?@'\:=3T;6)?$]A:R: MBGPV\=Z59SZ;_P`)'?Z;:1R:C>:'XATK[!I6M/81W=S8RZ5I%W'9FV&H31_V MMZ/_`,%,_P#@GQKFCVNN6'[9G[.']GW=LMVANOBWX,L;F*)EWE;NRO-6AN[. M=`");>YABGB8%9(U8$5]MG%'Q'\-\VGEV1X_/,=DRA2>75I8668X*K2G"#G2 M^KSI8JAA:U*MSTY4J:I5%%1J0]RK&4O-PLLFSS#^WQ&'PL,0^:-:#E&%:$HZ M#[R34_!^NZE8Q/<7>D&>:&WO=*UB*U1[Q-+U>UL[VXLDDN[>&2"-W7[#_ M`.#?[]M?Q9^S)^W)X!^$=WK5^?@[^T[K^G?#3Q=X:WH^G0>.M8233?AOXO@A MEQ]GU&U\0S6/A^^N89$\_0]7N/M4=PVGV'V?]#O^#AW_`(*E_LN?M-?!GP%^ MRS^SIXMT?XO7^G_%+2_B9XT^(6@1F]\)^';?PQH7B;1-.T+P_KS(MOJVL:U= M>)&GO+S1I+JRL])L+FRN;@3ZBD:?CK_P11_9U\0?M&_\%(_V;--TRTG?P]\* M_&^G?'+QSJBV\TUGI.@_"N=/%6G)>RQ(ZVXU_P`5V'A_PS:-(55KO6(@2$5V M7]HPV-QG$'AEF6+XWP$,!5J97FDL73J4)4&Z6&A4EA,;'"U6ZF'Q$ITZ=6A3 M=G*O"G5HQC&K2BOF'2I8//L/3RFLZL?:T$FI>T2Z[XN\2ZYJI_ZD4SPO\`X."]*T_4_P#@E!^TG+?6T=Q)I&H? M!W5=.=U!:TU"/XT>`;-;F(D$I)]EO;N`L,$Q3R)G#$'^$W_@EG_RDD_88_[. M>^$__J2VM?WA_P#!?S_E$Y^U+]/A!_ZO'X;U_!Y_P2S_`.4DG[#'_9SWPG_] M26UJ?"5O_B&/%*N[*OG[2OHF\CPEVETO97[V78TXA_Y'N`_Z\T/_`%(K'9?\ M%A/^4G/[:?\`V6S7?_2+3:^]/V[/^4#O_!(C_LHWQV_]2?XFU\%_\%A/^4G/ M[:?_`&6S7?\`TBTVOO3]NS_E`[_P2(_[*-\=O_4G^)M?^RZO3J>=0_B<2?]>,3_`.IL#YS_`.""7P2T3XX_\%/?@-8^)(;2 M\T/X96?C'XT7>G7L(GBU&_\``.BM_P`(O$L;`QL]CXRU?PYK6)08S%IV<8S7^=]_P`&T'_*3W2O^S?_`(P_^C_! MM?Z(I`(((!!!!!&00>""#P01P0>M?AGCQ6J3XPP=&4VZ5#(L(ZZFO?$GC[QEXG\:>(+NX*=;OM0ZC%'>S/IUG;R7%\L:?;9WDNF&Z8U\2?\`!2W]FN\_9+_;E_:. M^"K:9=:9X?TCXBZWXC\`+<1R*EU\-_&MU+XI\$3VLSJ%NH;?0]3MM*GGB+QK MJ.FWUL6$UO*B_P!K/_!%7_@HM^S1\<_V,/@U\,/B/XZ^%?@WX[_!;PKI?PE\ M0^#_`!/J/A_0]:\0Z)X$TZST7PGXRT:SU5X+C5K'5O#$&D+JEW:"=+;Q##J= MK,RD1&3]MXXSG`4.&HJS<. M6A.<8P5-SIIMQDTOF>88O"_7YY?B%S)M4XN5:4*EIPLYP2>O.E%R35V MKI7/Y:_CA_P6*_X*??M$?"3Q_P#!'XHQ:)JWP_\`B7X=N_#'BFPLO@[J-C>S M:;=F.0O97IO[C[)>6\\,-S:7/DRF"XACE"$J!7YN_L_:-\1/`_Q[^!WC6T$ M>+H+OP=\8OAAXKM)H]"UB-X[KPYXWT+6+9@Z6H8`3V2;@.&7*L"I(/\`HZ_M MN_\`!3/]B[]B_P"$WB[QEJWC'X5>._B58:'5I M%@T&F0ZG>:-HDMX\9U;Q%<6$MII=BL]QY=Q.L-K-^2O[#/\`P7P^)W[;O[4' MPL_9U\"_L+^"=/N/&.M+<^*?%$/Q)FNX?`_@71PM_P"+?&5U%_PKFW21=&TQ M'^PVTES:_P!HZS<:9I45Q'<7$/RF0\7YH\AS/'9)X983*LCIPQ-;&U?[6P> M4X>HJ>&3Q%>-.ME^'>(4*$5&56$9Q?*J:DY1<3T<7EE&6,P]+%Y[.MB[PC2I MK"NI--SBU'W*LE!RDVTIV=K2M;?^K*BBBOY1/O#^;C_@H3_P06US]HC]J.Z_ M;3_92^/FG_`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`ZM"]]H7BO4HO#-V`DGDYT;QA? MWD[P23-IMJCHE?F[D6NOX=LI00/[10YQ_9__`,$XO^":WP0_X)O?":\\#_#: M2Z\6>//%SV%]\4?BQK=I#::]XVU/3XYDLK6VL89;F'P_X7TAKJ\.B^'X+J\: MW-W<7-_J&I7TSW5?HK17R?%?B9Q/Q?0>"QU;#X3+92A.>7Y?2E1H594Y*4'7 MJ5:E?$UE&:4U3G6]BJD8S5)3C%KT,OR3`9=/VM"$IUK.*JU9<\XJ6Z@DE&-U MHVH\S6C=F[_Y\WQP_P"#>K_@IGX[^-7QA\;^'_AU\.)=`\8_%3XA^*=#FN?B MWX,MKB?1O$'B[6-5TN>:VDOQ);2SV-W!*]O*!+`SF*55D1E']HO_``3H^"?C M[]G#]B#]FSX&_%&QL=-^(/PT^'%EX;\5V.F:E:ZQ86NJPZAJ-S+%:ZG9/):7 ML0CN8R)X'9&)(SD$#[4HK+BGQ$SWB_+L%E>:4,MI8?`5X8BC+!8?$4JKG"A/ M#Q525;%XB,H\E23:C"+YK.Z2Y1X#)L)EU>KB,/*LYU82A)5)QE'EE.,]$H1: M:<4E>3TO>[U/SF_X*R_LW_%+]K?]@7XZ_`'X+Z=I>K?$KQTOP[_X1S3M9UBS MT#3KH^'OBEX*\3ZJ)]6U!H[*T,.C:-J%Q'Y\B">6%+>,F::-6_E;_85_X(+? M\%%_@1^V=^R[\:?B+X"^']AX#^%GQN\!>.?%]]IWQ2\(ZK?6F@>']:@OM1GM M=-M;YKJ^FC@C8QVUNCS2MA45CQ7]WM%+A[Q#SSAK(\?P_E]'+:F"S&>+G7GB MJ&(J8F+QN%IX.K[*=/%T:<5&E2C*GSTIVFY.7/&T4\9D^$QN*I8RM*LJM&$( M05.<8PM"WD=U92EH9`T$Z+( MH`)&"*^K?VI?^"0'[;7Q5_X)5_\`!/G]E/P?X/\`!MU\9/V>/&7Q2UCXF:1> M?$#PU8Z1IUAXJUSQO?:1+IVO3W:Z?JSRV^MZI_(!_P14_X([_M MO_L2_MO6/QR^/O@[P7H?P_M_A+\1/"+WVA?$+PUXEOAK7B.7PX^F0_V9I=W+ M=F&1=-NO,N!&8X=JB0C>N?Z_Z**^4XJXJS+C#,X9MFE/"4L3#"4L&HX*E5I4 M?949U:D6XUJ^(GSN5:?,^=1:Y4HJSOW8#`4,NH?5\.ZCI\\JG[R2E+FDDGK& M,5;W5;2^^I^3?_!4'_@DG\%?^"E?A31+S6=7;X6_'#P5;2V?@SXO:1H=IJ]U M-H[FZG'@_P`9Z8]QIT_B'PJ+ZZFO]/BCU2ROM!U&>YO=.G:"]U33M2_C8^/G M_!O5_P`%)_A%XNN=`\+?"32_CSX2?$FG^.?A?XET*YTNZC8EHX+WP_XGO/#_ M`(KT^^AVJ+E)M#>Q24@VFH7<2^=7^D717T?"GBEQ3PEAH8'"U<-C\NI\_L<% MF-.=2.&']'@>0>;<2:7HNI:WXLU'9N+>3HOAO49G;DH$WR+_9C_P2 MG_X)+?#+_@FAX*\270\06GQ3^.OQ`$,/C+XIR>'X]&_L[P_%'8S1^`O"%M+= M:A>V7AB+5;0ZIJ%U- EX-99.2 4 may1205_8k-ex9902.htm

EXHIBIT 99.02

Hampshire International Business Park
Chineham Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com

Press Release

12 May 2005

Shire Pharmaceuticals Group plc (the "Company")

The Company announces that on 11 May 2005 The Honourable James A. Grant, P.C., C.M., Q.C., a non-executive director of the Company, exercised an option granted to him under the BioChem Pharma Stock Option Plan and acquired 31,859 ordinary shares of £0.05p each in the Company at an option price of £2.50p per share.

As a result of this transaction The Honourable James Grant has an interest, excluding unexercised share options, in 68,269 ordinary shares of £0.05p each in the Company.

T May
Company Secretary

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160

	Brian Piper (North America)	+1 484 595 8252

Notes to editors

Shire Pharmaceuticals Group plc

For further information on Shire, please visit the Company’s website: www.shire.com.

-----END PRIVACY-ENHANCED MESSAGE-----